Poster

View content

• Congresses
• CLN2 Disease
• International Epilepsy Congress
• 2023

Cerliponase alfa for the treatment of CLN2 disease in a patient cohort including children <3 years old

A. Schulz, N. Specchio, E. De Los Reyes, P. Gissen, P. Slasor, S. Bondade, J. Cohen-Pfeffer

View content

Presentation

View content

• Congresses
• CLN2 Disease
• European Pediatric Neurology Society Congress
• 2023

Real-world clinical outcomes of intraventricular cerliponase alfa in CLN2 disease: Comparison with a historical cohort

A. Schulz, C. Schwering, E. Wibbeler, L. M. Westermann, L. Hagenah, S. Lezius, P. Slasor, P. Reisewitz, M. Nickel

View content

Poster

View content

• Congresses
• CLN2 Disease
• American College of Medical Genetics and Genomics
• 2023

Gene panels for skeletal dysplasia and epilepsy: Maximizing clinical utility through careful design, regular review, and clinician-laboratory collaboration

A. A. Tayoun, S. Aradhya, M. Bailey, L. Bastaki, S. Došenović, F. Ezgü, E. Izzo, C. Lampe, J. J. O’Byrne, G. Seratti, C. Snow, C. Staufner, P. Striano

View content

Poster

View content

• Congresses
• CLN2 Disease
• American Epilepsy Society Annual Meeting
• 2021

Clinical Utility of a Sponsored Gene Panel Testing Program for Pediatric Epilepsy and CLN2 Disease Diagnosis: Results from 14,589 Tests

T. Pang, S. Poll, D. A. McKnight, B. Johnson, A. Morales, S. L. Bristow, A. Mitchell, E. Izzo, G. Seratti, S. Koh, E. C. Wirrell, J. J. Millichap, S. Aradhya

View content

Presentation

View content

• Congresses
• CLN2 Disease
• International Child Neurology Congress
• 2022

Seizures in Children with CLN2 Disease Receiving Cerliponase Alfa for >5 Years

M. Nickel, A. Schulz

View content

Poster

View content

• Congresses
• CLN2 Disease
• European Pediatric Neurology Society Congress
• 2022

Long-Term Treatment with Intracerebroventricular Cerliponase Alfa for Children with CLN2 Disease: Safety and Efficacy after >5 Years

A. Schulz, E. de los Reyes, N. Specchio, P. Gissen, P. Slasor, S. Bondade, J. Cohen-Pfeffer

View content

Poster

View content

• Congresses
• CLN2 Disease
• WORLDSymposium
• 2022

Long-Term Treatment with Intracerebroventricular Cerliponase Alfa for Children with CLN2 Disease: Safety and Efficacy after >5 Years

A. Schulz, E. de los Reyes, N. Specchio, P. Gissen, P. Slasor, S. Bondade, J. Cohen-Pfeffer

View content

Presentation

View content

• Congresses
• CLN2 Disease
• International Epilepsy Congress
• 2021

Cerliponase alfa for the treatment of CLN2 disease in an expanded patient cohort including children younger than three years: Interim results from an ongoing clinical study

A. Schulz

View content

Presentation

View content

• Congresses
• CLN2 Disease
• European Human Genetics Conference
• 2021

Diagnostic yield and clinical utility of genetic testing in children with seizure onset after two years of age: Update over a 3-year program in Europe and the Middle East

A. Singh, K. Gall, E. Izzo, K. Alakurtti, E. H. Seppala, L. Koskinen, J. Koskenvuo, T. P. Alastalo

View content

Poster

View content

• Congresses
• CLN2 Disease
• WORLDSymposium
• 2021

Cerliponase Alfa for the Treatment of CLN2 Disease in an Expanded Patient Cohort Including Children Younger than Three Years: Interim Results from an Ongoing Clinical Study

A. Schulz, E. de los Reyes, N. Specchio, P. Gissen, P. Slasor, S. Bondade, D. Jacoby

View content